DUBLIN--(BUSINESS WIRE)--The "Targeting the CD47-SIRPA Axis in Oncology: A Competitive Assessment of Technologies, Dual Targeting, Biomarkers, Combination Therapies & More" report has been added to ResearchAndMarkets.com's offering.
Targeting the CD47-SIRP axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response. This report reveals intense global interest and a growing list of stakeholders operating in this field. Users of this report get an un-biased, fact driven analysis of the position of each molecule and commercial player, always kept up to date with twice weekly updates.
Most of the identified molecules in this report are either anti-CD47 antibodies or SIRP-Fc recombinant proteins. In healthy cells, CD47 serves as a "don't eat me" signal by binding to the transmembrane SIRP protein on phagocytic cells, preventing the engulfment of "self" by macrophages. In several cancer types, tumor cells overexpress CD47 to elude the immune system. Exploration of this property has been the driving force to attract hundreds of million of dollars in investments to companies like Tioma Therapeutics, Surface Oncology and Forty Seven, the latter of which has just recently completed a $113 million IPO of its common stock on June 26th, 2018. Deals in this area include the early adopter move in 2012 by Celgene securing Inhibrx' anti-CD47 antibody in a $500 million dollar deal to the recent billion dollar plus agreement between OSE Immunotherapeutics and Boehringer Ingelheim.
On the clinical development front, this report identifies fewer than ten molecules targeting the CD47-SIRP axis which have made it into the clinic and so far with encouraging results. Several of these trials also shed light on biomarker- and combination therapies of interest. On the horizon, this field will soon have another injection of candidate therapies with bispecific CD47 antibodies entering the clinic in late 2018 or early 2019.
Moreover, targeting the CD47-SIRP axis also has the potential to become the combination therapy of choice as has already been demonstrated via mediating longer survival in mice together with oncolytic virotherapy and enhancing phagocytic capacity when used together with Carisma Therapeutics' CAR macrophages. Carisma Therapeutics themselves have just announced a $53 million series A round of financing in order to develop its novel CAR macrophage cellular immunotherapy and is estimating that their project(s) will enter into the clinic in 2019.
Key Topics Covered
1 CD47-SIRPa Based Therapies in Oncology: An Overview
2 Startups Targeting the CD47-SIRPa Axis
3 Bispecific Drugs Targeting the CD47-SIRPa Axis
4 Deals & Alliances Among CD47-SIRPa Targeting Drugs
5 Phase II Pipeline Review & Analysis of CD47-SIRPa Based Therapies
6 Phase I Pipeline Review & Analysis of CD47-SIRPa Based Therapies
7 Preclinical Pipeline Review & Analysis of CD47-SIRPa Based Therapies
8 Discovery Pipeline Review & Analysis of CD47-SIRPa Based Therapies
9 CD47-SIRPa Based Therapies in Solid Tumors
10 CD47-SIRPa Based Therapies in non-Hodgkin's Lymphoma
11 CD47-SIRPa Based Therapies in Acute Myelogenous Leukemia
12 CD47-SIRPa Based Therapies in Acute Lymphocytic Leukemia
13 CD47-SIRPa Based Therapies in Myeloma
For more information about this report visit https://www.researchandmarkets.com/research/jdlw3w/targeting_the?w=4
